4.7 Article

High Risk of Diabetes and Neurobehavioral Deficits in Individuals With Surgically Treated Hyperinsulinism

Journal

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Volume 100, Issue 11, Pages 4133-4139

Publisher

ENDOCRINE SOC
DOI: 10.1210/jc.2015-2539

Keywords

-

Funding

  1. National Center for Research Resources [UL1RR024134]
  2. National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases [R01 DK098517, R37 DK056268, T32-DK63688-09]

Ask authors/readers for more resources

Context: Children with the most common and severe type of congenital hyperinsulinism (HI) frequently require pancreatectomy to control the hypoglycemia. Pancreatectomy increases the risk for diabetes, whereas recurrent hypoglycemia places children at risk of neurocognitive dysfunction. The prevalence of these complications is not well defined. Objective: The objective was to determine the prevalence of diabetes and neurobehavioral deficits in surgically treated HI. Design: This was designed as a cross-sectional study of individuals who underwent pancreatectomy for HI between 1960 and 2008. Outcomes: Diabetes outcomes were assessed through patient interview and medical record review. Neurobehavioral outcomes were assessed through the Adaptive Behavior Assessment System, 2nd edition (ABAS-II), and the Child Behavior Checklist (CBCL). Results: A total of 121 subjects were enrolled in the study at a median age of 8.9 years (range, 3.5-50.7 y). Thirty-six percent (44 of 121) of subjects had diabetes. Nine subjects developed diabetes immediately after pancreatectomy. Of the remaining 35 subjects who developed diabetes, the median age at diabetes diagnosis was 7.7 years (range, 8 mo to 43 y). In subjects with diabetes, the median hemoglobin A1c was 7.4% (range, 6.5-12.6%), and 38 (86%) subjects required insulin. Subjects with diabetes had a greater percentage of pancreatectomy than subjects without diabetes (95% [range, 65-98] vs 65% [1-98]). Neurobehavioral abnormalities were reported in 58 (48%) subjects. Nineteen (28%) subjects had abnormal ABAS-II scores, and 10 (16%) subjects had abnormal CBCL scores. Conclusions: Children, who undergo near-total pancreatectomy are at high risk of developing diabetes. Neurobehavioral deficits are common, and developmental assessment is essential for children with HI.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Critical Care Medicine

Islet Hormone and Incretin Secretion in Cystic Fibrosis after Four Months of Ivacaftor Therapy

Andrea Kelly, Diva D. De Leon, Saba Sheikh, Devaney Camburn, Christina Kubrak, Amy J. Peleckis, Darko Stefanovski, Denis Hadjiliadis, Michael R. Rickels, Ronald C. Rubenstein

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2019)

Article Endocrinology & Metabolism

Continuous Intragastric Dextrose: A Therapeutic Option for Refractory Hypoglycemia in Congenital Hyperinsulinism

Mary Ellen Vajravelu, Morgan Congdon, Lauren Mitteer, Jamie Koh, Stephanie Givler, Justine Shults, Diva D. De Leon

HORMONE RESEARCH IN PAEDIATRICS (2019)

Article Respiratory System

Dysregulated insulin in pancreatic insufficient cystic fibrosis with post-prandial hypoglycemia

Marissa J. Kilberg, Saba Sheikh, Darko Stefanovski, Christina Kubrak, Diva D. De Leon, Denis Hadjiliadis, Ronald C. Rubenstein, Michael R. Rickels, Andrea Kelly

JOURNAL OF CYSTIC FIBROSIS (2020)

Article Multidisciplinary Sciences

Activation of Protein Kinase A (PKA) signaling mitigates congenital hyperinsulinism associated hypoglycemia in the Sur1-/- mouse model

Mangala M. Soundarapandian, Christine A. Juliana, Jinghua Chai, Patrick A. Haslett, Kevin Fitzgerald, Diva D. De Leon

PLOS ONE (2020)

Article Genetics & Heredity

Heterozygous recurrent HNF4A variant p.Arg85Trp causes Fanconi renotubular syndrome 4 with maturity onset diabetes of the young, an autosomal dominant phenocopy of Fanconi Bickel syndrome with colobomas

Sarah E. Sheppard, Brett Barrett, Colleen Muraresku, Heather McKnight, Diva D. De Leon, Katherine Lord, Rebecca Ganetzky

Summary: Heterozygous pathogenic variants in HNF4A can result in a range of disorders, including hyperinsulinism and diabetes, with patients potentially exhibiting multiple features simultaneously. Specific pathogenic variants may also lead to the expansion of different clinical phenotypes.

AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2021)

Letter Obstetrics & Gynecology

What's in a name? That which we call perinatal stress hyperinsulinism by any other name would smell so bitter

Paul Thornton, Diva D. De Leon

JOURNAL OF PERINATOLOGY (2021)

Article Genetics & Heredity

PHKA2 variants expand the phenotype of phosphorylase B kinase deficiency to include patients with ketotic hypoglycemia only

Anne Benner, Yazeid Alhaidan, Matthew A. Lines, Klaus Brusgaard, Diva D. De Leon, Rebecca Sparkes, Anja L. Frederiksen, Henrik T. Christesen

Summary: Idiopathic ketotic hypoglycemia is a diagnosis of exclusion with differential diagnosis including glycogen storage diseases. Our study identified novel pathogenic PHKA2 variants associated with ketotic hypoglycemia, hepatomegaly, and growth retardation. The continuum of PHKA2 missense variants expands the classical GSD IXa phenotype.

AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2021)

Article Endocrinology & Metabolism

The Bihormonal Bionic Pancreas Improves Glycemic Control in Individuals With Hyperinsulinism and Postpancreatectomy Diabetes: A Pilot Study

Arpana Rayannavar, Lauren M. Mitteer, Courtney A. Balliro, Firas H. El-Khatib, Katherine L. Lord, Colin P. Hawkes, Lance S. Ballester, Edward R. Damiano, Steven J. Russell, Diva D. De Leon

Summary: The study aimed to determine if the bihormonal bionic pancreas (BHBP) improves glycemic control and reduces hypoglycemia in individuals with congenital hyperinsulinism (HI) and postpancreatectomy diabetes (PPD) compared with usual care (UC). The results showed that relative to UC, the BHBP resulted in comparable glycemic control in the study population.

DIABETES CARE (2021)

Article Oncology

Incidence and risk factors for hypoglycemia during maintenance chemotherapy in pediatric acute lymphoblastic leukemia

Elizabeth Rosenfeld, Kelly D. Getz, Tamara P. Miller, Alix E. Seif, Brian T. Fisher, Evanette Burrows, Mark Jason Ramos, Diva D. De Leon, Richard Aplenc, Knashawn H. Morales, James P. Guevara

Summary: This study found a high incidence of hypoglycemia during maintenance chemotherapy, with younger age at maintenance initiation and hepatotoxicity during chemotherapy prior to maintenance initiation being associated with this outcome. It highlights the importance of counseling and monitoring for hypoglycemia, especially in young children.

PEDIATRIC BLOOD & CANCER (2022)

Article Pediatrics

Congenital hyperinsulinism: localization of a focal lesion with 18F-FDOPA positron emission tomography

Lisa J. States, Susan A. Becker, Diva D. De Leon

Summary: Hyperinsulinemic hypoglycemia of infancy, also known as congenital hyperinsulinism, is a group of disorders characterized by dysregulated insulin release. Severe cases may require pancreatectomy to prevent brain damage from hypoglycemia, and surgical resection of a focal lesion can result in a cure in up to 97% of children. PET imaging with genetic evaluation is crucial for guiding surgical treatment.

PEDIATRIC RADIOLOGY (2022)

Article Endocrinology & Metabolism

Exendin-(9-39) Effects on Glucose and Insulin in Children With Congenital Hyperinsulinism During Fasting and During a Meal and a Protein Challenge

Darko Stefanovski, Mary E. Vajravelu, Stephanie Givler, Diva D. De Leon

Summary: The aim of this study was to assess the effects of exendin-(9-39) on fasting and postprandial plasma glucose and the incidence of hypoglycemia in children with hyperinsulinism. The results showed that exendin-(9-39) significantly increased fasting and postprandial glucose and reduced the likelihood of hypoglycemia.

DIABETES CARE (2022)

Article Endocrinology & Metabolism

The Use of Lanreotide in the Treatment of Congenital Hyperinsulinism

Heather Cuff, Katherine Lord, Lance Ballester, Tryce Scully, Nicole Stewart, Diva D. De Leon

Summary: This study evaluated the effectiveness and safety of lanreotide in individuals with HI, showing that lanreotide is a well-tolerated treatment resulting in a longer duration of fasting and simplification of treatment regimens.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2022)

Article Pediatrics

Undiagnosed hypoglycaemia disorders in children detected when hypoglycaemia occurs in the setting of illness: a retrospective study

Elizabeth Rosenfeld, Ohoud Alzahrani, Diva D. De Leon

Summary: The study aimed to determine whether incidental hypoglycaemia detected during intercurrent illness in children requires an endocrine workup and to compare clinical and biochemical features between patients ultimately diagnosed with a hypoglycaemic disorder and those who were not. The study found that 8% of the patients who underwent a diagnostic fast were diagnosed with a hypoglycaemic disorder, suggesting that diagnostic evaluation is necessary for hypoglycaemia detected during illness.

BMJ PAEDIATRICS OPEN (2023)

Article Endocrinology & Metabolism

International Guidelines for the Diagnosis and Management of Hyperinsulinism

Diva D. De Leon, Jean Baptiste Arnoux, Indraneel Banerjee, Ignacio Bergada, Tricia Bhatti, Louise S. Conwell, Jun Fen Fu, Sarah E. Flanagan, David Gillis, Thomas Meissner, Klaus Mohnike, Tai L. S. Pasquini, Pratik Shah, Charles A. Stanley, Adrian Vella, Tohru Yorifuji, Paul S. Thornton

Summary: Hyperinsulinism (HI) is the most common and severe cause of persistent hypoglycemia in infants and children. Despite advances in diagnostic tools and understanding of the pathophysiology, there is currently only one approved drug for treating HI, and it is unavailable in many under-developed regions. This international consensus statement aims to aid in early recognition and treatment of HI, with the goal of reducing brain injury caused by hypoglycemia.

HORMONE RESEARCH IN PAEDIATRICS (2023)

Article Endocrinology & Metabolism

Dasiglucagon for the Treatment of Congenital Hyperinsulinism: A Randomized Phase 3 Trial in Infants and Children

Paul S. Thornton, Diva D. De Leon, Susann Empting, David Zangen, David M. Kendall, Sune Birch, Eva Boge, Jelena Ivkovic, Indraneel Banerjee

Summary: This study evaluated the efficacy and safety of continuous subcutaneous infusion of dasiglucagon as an add-on treatment for children with CHI and persistent hypoglycemia. Dasiglucagon was found to significantly reduce the frequency and severity of hypoglycemic episodes, and was well tolerated.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2023)

No Data Available